title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Results | PMC10646994 | |||
Baseline characteristics | Stroke | STROKE | Of 948 enrolled patients in the RESCUE BT study, 435 had intracranial LAA etiology, 197 in the intravenous tirofiban group, among whom 175 (88.8%) had successful reperfusion, and 238 in the placebo group, among whom 207 (87.0%) had successful reperfusion (eTICI 2b50‐3) (Fig. Flowchart.Baseline characteristics and workf... | PMC10646994 |
Primary efficacy outcome | Stroke, Thrombolysis, Cerebral Infarction | REGRESSION, CEREBRAL INFARCTION, STROKE | Treatment with intravenous tirofiban was associated with independent functional outcome (mRS 0 to 2) at 90 days in 54.3% (95 out of 175) patients in the tirofiban group and 44.0% (91 out of 207) patients (44.0%) in the placebo group (adjusted odds ratio [aOR], 1.58; 95% CI, 1.02–2.44; Efficacy and safety outcomes.CI, c... | PMC10646994 |
Secondary efficacy outcomes | SECONDARY | The secondary clinical efficacy outcomes were shown in Table | PMC10646994 | |
Safety outcomes | sICH | At 90 days, no significant difference was observed between the two groups in the incidence of sICH, 12 out of 175 (6.9%) versus 11 out of 207 (5.3%) (aOR, 1.41; 95% CI, 0.59–3.34; Safety outcomes of the cohort. | PMC10646994 | |
Subgroup analyses | SECONDARY | The effects of tirofiban stratified by reperfusion grade on the primary outcome, the secondary efficacy outcomes, and primary safety outcomes were shown in Figure Heterogeneity analysis for intravenous tirofiban effect on outcomes with stratified reperfusion grades.There was no significant heterogeneity of effect of th... | PMC10646994 | |
Discussion | death, sICH, intracranial hemorrhage, stroke, cardioembolic, hemorrhagic transformation, infarcts, ischemic stroke, hemorrhage, LAA stroke, artery atherosclerotic disease, acute ischemic stroke | INTRACRANIAL HEMORRHAGE, STROKE, ISCHEMIC STROKE, HEMORRHAGE, SECONDARY | This study focused on the population of patients with acute ischemic stroke due to intracranial large artery atherosclerotic disease, which is a main cause of stroke in Asian patients and a determinant of poor outcome. Randomized studies evaluating the outcome of EVT in patients with intracranial LAA were sparse. Among... | PMC10646994 |
Conclusions | intracranial hemorrhage, vessel occlusion, artery atherosclerotic stroke | INTRACRANIAL HEMORRHAGE | Among patients with large vessel occlusion due to large artery atherosclerotic stroke and successful reperfusion after endovascular thrombectomy, adjunct intravenous tirofiban was associated with a higher rate or independent functional outcome, without higher rates of symptomatic intracranial hemorrhage or mortality. C... | PMC10646994 |
Author Contributions | Dr Wenjie Zi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. | PMC10646994 | ||
Funding Information | This study was funded by National Natural Science Foundation of China (No.82071323). | PMC10646994 | ||
Conflict of Interest | Dr Saver reported receiving contracted hourly payments for service on clinical trial steering committees advising on rigorous trial design and conduct from Medtronic, Cerenovus, NeuroVasc, Boehringer Ingelheim (prevention only);stock options for service on Clinical Trial Steering Committees advising on rigorous trail d... | PMC10646994 | ||
Patient Consent for Publication | Not applicable. | PMC10646994 | ||
Ethics Approval | This study was approved by the ethics of the Xinqiao Hospital, Army Medical University and all participating centers. Written informed consent was obtained from all the patients or their legally authorized representatives. | PMC10646994 | ||
Supporting information |
Click here for additional data file. | PMC10646994 | ||
Acknowledgments | We thank all study participants for their contribution to the study and the research staff at all the participating hospitals. | PMC10646994 | ||
Data Availability Statement | Data are available upon reasonable request. | PMC10646994 | ||
References | PMC10646994 | |||
Subject terms | CAD | CORONARY ARTERY DISEASE, CAD | Systematic exercise training effectively improves exercise capacity in patients with coronary artery disease (CAD), but the magnitude of improvements is highly heterogeneous. We investigated whether this heterogeneity in exercise capacity gains is influenced by the insertion/deletion (I/D) polymorphism of the angiotens... | PMC10600103 |
Introduction | CAD, death | CORONARY ARTERY DISEASE, CAD, DELETION | Coronary artery disease (CAD) is a leading cause of death worldwideImportantly, there is substantial inter-individual variability in the response to systematic exercise training, with training-induced improvements in VOA potentially decisive determinant of exercise capacity adaptability is the insertion (I) and deletio... | PMC10600103 |
Methods | PMC10600103 | |||
Patients and study design | CAD | CAD | A total of 169 patients older than 18 years with angiographically confirmed CAD were recruited for the study, and parts of the obtained data have been reported elsewherePatient characteristics.Anthropometrics are presented as means ± standard deviation, and dichotomous data are expressed as numbers (percentages) in pat... | PMC10600103 |
Exercise training | The prescribed exercise training programme has been described in detail previously | PMC10600103 | ||
ACE genotyping | Determination of the patients’ ACE genotype was performed as previously described | PMC10600103 | ||
Exercise capacity measurements | Patients reported to the exercise laboratory in a fasted state (> 1.5 h) and were explicitly told to refrain from tobacco, caffeine and alcohol on testing day and to avoid strenuous exercise for at least 24 h prior to exercise testing.Peak oxygen uptake (VOThe exercise protocol was conducted on a cycle ergometer to ens... | PMC10600103 | ||
Statistics | Anthropometric and baseline exercise capacity measurements are presented as means with standard deviation and compared using a one-way ANOVA. Proportions are expressed in percentages and compared by Pearson’s chi-squared test if model assumptions were met and otherwise by Fisher’s exact test.Changes in exercise capacit... | PMC10600103 | ||
Results | The ACE I/D genotype distribution was n = 48 for D/D, n = 61 for I/D and n = 19 for I/I. As illustrated in Table | PMC10600103 | ||
ACE genotype and pre-training exercise capacity | All obtained measures of exercise capacity were similar between genotype groups at baseline (Table Baseline exercise capacity.Values are presented as means ± standard deviations for patients with the ACE D/D, I/D or I/I genotype. The | PMC10600103 | ||
Exercise training | For the patients allocated to exercise training, the ACE genotype distribution was n = 26, n = 21 and n = 12 for D/D, I/D and I/I, respectively. Patients with the ACE D/D, ACE I/D or ACE I/I genotype had similar gender and ACE inhibitor treatment distribution and were comparable in age, height, weight and BMI (Table Pa... | PMC10600103 | ||
Exercise power output and relative intensity | The average power output during the exercise intervals was similar between genotype groups (D/D: 139 ± 39 W vs. I/D: 139 ± 54W vs. I/I: 120 ± 42 | PMC10600103 | ||
ACE genotype and exercise capacity improvements | Twelve weeks of exercise training effectively increased (The figure shows mean values for peak oxygen uptake adjusted for body weight (The figure shows mean values for peak oxygen uptake adjusted for body weight ( | PMC10600103 | ||
ACE genotype and steady-state VO | No significant within-group or between-group effect existed for changes in steady-state VOThe figure shows mean values for oxygen uptake at 30/50W (females/males) (The figure shows mean values for oxygen uptake at 30/50W (females/males) ( | PMC10600103 | ||
Carriers of the I allele versus D/D homozygotes | Due to the low frequency of ACE I/I homozygotes and to ensure a more balanced genotype distribution in the statistical analysis, a sub-analysis, in which carriers of the I allele were combined into a single group (I/ +), was conducted. Patients with the ACE D/D or I/ + genotype had similar gender and ACE inhibitor trea... | PMC10600103 | ||
Discussion | CAD | CAD | We investigated the significance of the ACE I/D genotype for pre-training exercise capacity and whether the ACE I/D genotype impacts the outcome of 12 weeks of whole-body high-intensity interval training on exercise capacity in patients with stable CAD. The pre-training exercise capacity was independent of the ACE geno... | PMC10600103 |
ACE genotype and exercise capacity | cardiovascular conditionsIn | Exercise capacity is a powerful predictor of the risk of all-cause mortality in patients with cardiovascular conditionsIn our study, we assessed the impact of the ACE I/D genotype on baseline exercise capacity and training-induced adaptations in exercise capacity, since previous research has reported that the I/I genot... | PMC10600103 | |
ACE genotype and muscular efficiency | Muscular efficiency is critical for endurance performance | PMC10600103 | ||
Strengths and limitations | It is a strength that we recruited a well-described clinical population in which improvement in exercise capacity is highly important. The adherence to the prescribed supervised exercise sessions was high and the drop-out was low, which is a strength. The sample size is relatively high in terms of a training study, but... | PMC10600103 | ||
Conclusion | CAD | CAD | Both baseline exercise capacity and exercise capacity improvements following 12 weeks of whole-body low-volume high-intensity exercise training seem to be independent of the ACE genotype in patients with CAD. Thus, the present findings do not support a clinically important role for the ACE genotype as a modulator of in... | PMC10600103 |
Acknowledgements | The authors want to express their sincere gratitude to all the study participants for their keen commitment and determined participation, and to the laboratory technicians Gunnrið Jóanesarson and Nina Djurhuus for their assistance in the ACE genotyping process. Finally, the rowing specialist, Toni Dam, is acknowledged ... | PMC10600103 | ||
Author contributions | T.S., J.K., N.B.N., E.L.G., A.M.H., S.D.K. and M.M. conceived and designed the research. T.S., J.K., L.N.L. and N.O.G. performed the experiments. T.S. and J.K. analyzed the data. T.S., J.K. and M.M. interpreted the results of the experiments. T.S. prepared the figures and drafted the manuscript. All authors edited and ... | PMC10600103 | ||
Funding | The present study was supported by the Research Council Faroe Islands (project number 0352) and the National Hospital of the Faroe Islands. | PMC10600103 | ||
Data availability | The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. | PMC10600103 | ||
Competing interests | N.O.G. | The authors report the following general conflicts. E.L.G. has no conflicts related to the present study but has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, MSD, Novo Nordisk, Lundbeck Pharma and Organon. He is serving as investigator in cl... | PMC10600103 | |
References | PMC10600103 | |||
1. Introduction | obesity, weight loss, metabolic disorders | OBESITY, OBSTRUCTIVE SLEEP APNEA, ARTHROPATHIES, METABOLIC DISORDERS | Background: Protein-sparing modified fast (PSMF) diet is a very-low-carbohydrate ketogenic diet administered to patients with obesity, which preserves lean mass and suppresses appetite as well as continuous enteral feeding. Thus, we aim to evaluate the effect of the PSMF diet administered continuously by nasogastric tu... | PMC10674249 |
2. Materials and Methods | PMC10674249 | |||
2.1. Study Design and Subjects | obesity | OBESITY | The present study is a pilot single-center randomized clinical trial designed to test the efficacy of a PSMF diet administered via NGT (ProMoFasT) compared with the same PSMF diet taken orally in patients with obesity. Subjects were evaluated and enrolled in the Dietetics and Clinical Nutrition Unit of the IRCCS Policl... | PMC10674249 |
2.2. Nutritional Protocol | Patients were randomized 1:1 to a PSMF diet administered continuously during 24 h via NGT (ProMoFasT) or to the same PSMF diet administered orally. The protocol included 5 cycles of active PSMF nutrition lasting 10 days alternated to 20 days of a balanced oral low-calorie diet for a total of 150 days. The PSMF diet adm... | PMC10674249 | ||
2.3. Naso-Gastric Tube Placement and Home’s Enteral Nutrition Management | After a 12-h overnight fast, an 8 French polyurethane NGT was placed in a day-hospital setting in the Dietetics and Clinical Nutrition Unit of the IRCCS Policlinic San Martino Hospital, University of Genoa, Italy. Patients were provided with tools to carry out home EN and they were elucidated about the use of the infus... | PMC10674249 | ||
2.4. Statistical Analysis | IBM SPSS Statistics, Version 25.0 (SPSS Inc., Chicago, IL, USA, | PMC10674249 | ||
3. Results | PMC10674249 | |||
3.1. Study Population | Twenty patients (75.0% females and 25.0% males; median age 49.0 years, IQR 41.0–53.0) were randomized to the administration via NGT (ProMoFasT group), while 24 patients (58.3% females and 41.7% males; mean age 49.0 years, IQR 39.0–56.5) were assigned to the PSMF diet administration orally (oral group) ( | PMC10674249 | ||
3.3. Biochemical Parameters | TG | As shown in TC, LDL-C and TG plasma levels were significantly reduced, and HDL-C plasma levels were significantly increased in the ProMoFasT group from baseline to follow-up visit, while TC, HDL-C and LDL-C levels were significantly increased, and TG levels were significantly reduced in the oral group from baseline to ... | PMC10674249 | |
4. Discussion | obesity, MM, FM, appetite suppression, weight loss, TG, glucometabolic | OBESITY, SEVERE OBESITY, INSULIN RESISTANCE | VLCKDs are valid and well-recognized strategies in the treatment of severe obesity and the PSMF diet falls into this group of dietary interventions, but its peculiarity is that not only carbohydrates are restricted to less than 30 g/day, but also lipids are limited to less than 20 g/day, making proteins the primary sou... | PMC10674249 |
5. Conclusions | SEVERE OBESITY | Compared to the same PSMF diet given orally, the ProMoFasT is an effective and safe nutritional intervention that has a good compliance rate and results in improvements in body composition with an insulin-lowering effect among subjects with severe obesity. Further RCTs are needed to confirm these preliminary findings. | PMC10674249 | |
Author Contributions | Conceptualization, S.G.S.; formal analysis, I.S. and E.F.; investigation, R.G. and C.R.; data curation P.G. and C.R.; writing—original draft preparation, E.F.; writing—review and editing, L.P. and S.G.S.; supervision, S.G.S. All authors have read and agreed to the published version of the manuscript. | PMC10674249 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of IRCCS Policlinic San Martino Hospital, University of Genoa (Italy) on 15 February 2011 (n.reg CEA 125/10). | PMC10674249 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10674249 | ||
Data Availability Statement | Data for the reported results are available upon a reasonable request, in accordance with ethical principles. | PMC10674249 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC10674249 | ||
References | muscle mass, FM | BLOOD, INSULIN RESISTANCE | The CONSORT flowchart of the study. Abbreviations: ITT: intention-to-treat; ProMoFasT: Protein-Sparing Modified Fast diet by nasogastric tube.Comparison of the body weight between the two groups. Abbreviations: ProMoFasT: Protein-Sparing Modified Fast diet by nasogastric tube.Comparison of the muscle mass (%) and the f... | PMC10674249 |
Introduction | hypovolemia, IDH | INTRADIALYTIC HYPOTENSION, PATHOGENESIS, COMPLICATION | Intradialytic hypotension (IDH) is a common clinical complication and is associated with increased morbidity and mortality in patients undergoing maintenance hemodialysis (MHD). The pathogenesis of IDH has been attributed to the rapid reduction of plasma volume during hemodialysis and the inadequate compensatory mechan... | PMC10176680 |
Methods | We performed a post-hoc analysis of a double-blind, placebo-controlled, randomized, 2 × 2 crossover clinical trial comparing the continuous infusion of icatibant, a bradykinin B | PMC10176680 | ||
Results | reduction of systolic blood pressure, IDH | Seven of the patients had IDH, defined as a reduction of systolic blood pressure equal to or greater than 20 mmHg during hemodialysis. Stratified analysis, based on the presence of IDH, revealed that icatibant prevented the decrease in blood pressure compared to placebo in patients with IDH [blood pressure at average n... | PMC10176680 | |
Conclusion | IDH | Bradykinin B2 receptor blocker may prevent the occurrence of IDH. Further studies should evaluate the hemodynamic effects of icatibant during hemodialysis and the symptomatology associated with IDH. | PMC10176680 | |
Supplementary Information | The online version contains supplementary material available at 10.1186/s12882-023-03192-4. | PMC10176680 | ||
Keywords | PMC10176680 | |||
Introduction | nausea, ESKD, intradialytic hypotension, cramps, dizziness, headache, hypovolemia, IDH | COMPLICATION OF HEMODIALYSIS, INTRADIALYTIC HYPOTENSION, END-STAGE KIDNEY DISEASE, PATHOGENESIS | Patients with end-stage kidney disease (ESKD) on maintenance hemodialysis (MHD) have a decreased life expectancy and increased mortality risk [Intradialytic hypotension (IDH), a common clinical complication of hemodialysis, is defined as a decrease in systolic blood pressure (SBP) of 20 mmHg or more, and it is usually ... | PMC10176680 |
Materials and methods | PMC10176680 | |||
Study population | acute infection, myocardial infarction, malignancy, liver disease, cough, angioedema | ACUTE INFECTION, MYOCARDIAL INFARCTION, EVENT, LIVER DISEASE, ANGIOEDEMA, CONNECTIVE TISSUE DISEASE, GASTROINTESTINAL DYSFUNCTION | The study was approved by the Vanderbilt University Institutional Review Board and performed according to the Declaration of Helsinki. Two-hundred and two patients were pre-screened for eligibility, and 16 patients were approached and assessed for eligibility. Patients with a history of functional transplant less than ... | PMC10176680 |
Study protocol | hemodialysisIntradialytic hypotension, hypotension | The study procedures were performed in the Vanderbilt University General Clinical Research Center (GCRC). Patients participated in a randomized placebo-controlled two by two crossover study, in which they received either, the bradykinin B
Study design. The study was a randomized, cross-over, double-blind, placebo-contr... | PMC10176680 | |
Laboratory procedures | For bradykinin measurements, blood was collected into polypropylene tubes containing chilled ethanol and let the mixture stand for 30 min at 4 °C. Samples were then centrifuged and the supernatant was stored frozen at -80 until processing. Bradykinin was measured by high-perfomance liquid chromatography (HPLC) followin... | PMC10176680 | ||
Statistical methods | intradialytic hypotension | INTRADIALYTIC HYPOTENSION | Data are presented as mean ± SEM or median and interquartile range. We also estimated the area under the curve for the change from baseline over time in blood pressure and heart rate, calculated by summing the numerical values of successive linear segments for every 15 min intervals. We used McNemar’s test to compare t... | PMC10176680 |
Results | PMC10176680 | |||
Baseline patient characteristics | Baseline characteristics are shown in Table
Baseline characteristicsACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. Data are presented as mean ± SD | PMC10176680 | ||
Effect of hemodialysis and bradykinin receptor blockade on blood pressure | reduction of blood pressure, decrease in systolic blood pressure, IDH, intradialytic hypotension | INTRADIALYTIC HYPOTENSION, HEART | Icatibant treatment did not affect blood pressure during hemodialysis compared to placebo treatment in the overall group (Figure We next analyzed the effect of icatibant on blood pressure in patients with and without intradialytic hypotension.The hemodialysis variables in patients with and without intradialytic hypoten... | PMC10176680 |
Effect of icatibant on bradykinin concentrations | hypotension, intradialytic hypotension | INTRADIALYTIC HYPOTENSION | Bradykinin concentrations were measured prior to, at the beginning of hemodialysis, at 30, and 60 min after initiation of hemodialysis. There was no effect of icatibant versus placebo on bradykinin levels during hemodialysis. In addition, patients who experienced intradialytic hypotension had similar bradykinin levels ... | PMC10176680 |
Adverse events | dizziness, cramps, hypotension | ADVERSE EVENT | There was no adverse event related to the study intervention. Three patients delevop symptoms associated with hypotension. All of them reported cramps and one of them also complain of dizziness. | PMC10176680 |
Discussion | dialysis-induced hypotension, hypovolemia, hemodialysis-induced hypotension, intradialytic hypotension | COMPLICATION OF HEMODIALYSIS, INTRADIALYTIC HYPOTENSION, VASODILATION, HEREDITARY ANGIOEDEMA | In this pilot study, we found that bradykinin BThe lack of vasoconstriction in response to hypovolemia is one of the impaired responses during intradialytic hypotension. Previous studies suggest that vasopressin, nitric oxide, and adenosine are associated with the occurrence of intradialytic hypotension [Bradykinin is ... | PMC10176680 |
Acknowledgements | WRIGHT | We would to thankc Patricia Wright, Anthony Dematteo, and Shouzuo Wei for their valuable technical assistant. We also like to thank all the participants for their dedication to the study. | PMC10176680 | |
Authors’ contributions | CM | The study design was contributed by JLG, NJB, and TAI. The formal analysis was contributed by JLG, HN, and CY. Writing the original draft was contributed by JLG, NJB, TAI. Experiment and data acquisition were contributed by JLG, CM, and AC. Writing and editing the manuscript were contributed by JLG, CM, AC, HN, CY, TAI... | PMC10176680 | |
Funding | This study is supported in part by 1UL-1RR024975 and K23DK100533 grants from the National Institutes of Health, and drug supply through Investigator-Initiated Research Support (IIR-USA-000344 from Shire/Takeda). The sponsors did not influence the design, execution, and analysis of the results of the study. | PMC10176680 | ||
Data Availability | The data that support the findings of this study are included in the article and supplementary material. Further inquiries can be directed to the corresponding author. | PMC10176680 | ||
Declarations | PMC10176680 | |||
Ethics approval and consent to participate | All the study participants had given written informed consent before enrollment. Prior to the initiation of the study, we obtained approval from Vanderbilt Institutional Review Board (IRB #131602). This study was conducted in accordance with the Declaration of Helsinsky. | PMC10176680 | ||
Consent for publication | Not applicable. | PMC10176680 | ||
Competing interests | BROWN | Shire/Takeda provided icatibant for the study through an Investigator Initiated Research Support grant. Drs. Brown and Gamboa serve as consultants to Pharvaris. Dr. Brown serves on the scientific advisory board for Alnylam Pharmaceuticals. The remaining authors have declared no conflict of interests. | PMC10176680 | |
References | PMC10176680 | |||
Background | breast cancer | MPBC, BREAST CANCER | Metaplastic breast cancer (MpBC) is a rare histological subtype of breast cancer. This study aims to establish a competitive risk model for older women with MpBC to predict patients’ survival accurately. | PMC10349515 |
Methods | death | MPBC | Data on patients diagnosed with MpBC from 2010 to 2019 are from the Surveillance, Epidemiology and End Results (SEER) program in the United States. All patients were randomly assigned to the training set and validation set. The proportional sub-distribution risk model was used in the training set to analyze the risk fa... | PMC10349515 |
Results | tumor | MPBC, TUMOR | One thousand, four hundred twelve older women with MpBC were included in this study. Age, T stage, N stage, M stage, tumor size, surgery and radiotherapy were risk factors for CSM. We established a competitive risk model to predict 1-, 3-, and 5-year cancer-specific survival in older women with MpBC. The C-index of the... | PMC10349515 |
Conclusion | MPBC | We developed a competitive risk model based on these risk factors to predict cancer-specific survival in older women with MpBC. The validation results of the model show that it is a very effective and reliable prediction tool. This predictive tool allows doctors and patients to make individualized clinical decisions.
| PMC10349515 | |
Supplementary Information | The online version contains supplementary material available at 10.1186/s12905-023-02513-x. | PMC10349515 | ||
Keywords | PMC10349515 | |||
Introduction | cancer, Breast cancer, breast cancers, breast cancer | BREAST CANCER RECURRENT, BREAST CANCER, MPBC, CANCER, BREAST CANCER | Breast cancer is the most common cancer in women. Metaplastic breast cancer (MpBC) is a rare histological subtype, accounting for 0.25–2% of breast cancers [Breast cancer is widespread in older women. However, because of the lack of standard treatment for older breast cancer patients, undertreatment leads to higher rat... | PMC10349515 |
Materials and methods | PMC10349515 | |||
Data resources | cancer, tumor | MPBC, TUMOR, CANCER | Data on patients diagnosed with MpBC from 2010 to 2019 are from the Surveillance, Epidemiology and End Results (SEER) program. The SEER database is a population-based cancer database in the United States, including 18 cancer registries, covering about 30% of the US population. Since the patient’s personal information i... | PMC10349515 |
Variables definition | squamous cell carcinoma, spindle cell carcinoma, tumor, death, cancer, adenosquamous carcinoma, adenocarcinoma, metaplastic carcinoma | CANCER, TUMOR, ADENOCARCINOMA | The clinicopathological information of patients, including age, race, marriage, histological type, histological grade, TNM stage, ER, PR and HER2 status, tumor size, and treatment (surgery, radiotherapy and chemotherapy), were obtained from the SEER database. The race is divided into white, black and others (American I... | PMC10349515 |
Development and validation of the competitive risk model | In order to ensure the accuracy of model validation, we divided the data into two relatively independent datasets. All patients were randomly assigned to the training set (70%) and validation set (30%). In the training set, the proportional sub-distribution risk model proposed by Fine and Gray [ | PMC10349515 | ||
Clinical utility | Decision Curve Analysis (DCA) is a new algorithm to calculate the net profit under different thresholds. DCA was used to calculate the potential clinical value of the new model and compared it with the traditional TNM staging system. In addition, according to the risk value calculated by the competitive risk model, the... | PMC10349515 | ||
Statistical analysis | All statistical methods were analyzed by R software 4.1.0 and SPSS 26.0. Continuous variables were described by mean and standard deviation, and a nonparametric U test was used to compare differences between groups. Categorical variables were described by frequency, and chi-square tests were used to compare group diffe... | PMC10349515 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.